Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders

John S. Tzartos; Fotini Boufidou; Christos Stergiou; Jens Kuhle; Eline Willemse; Lina Palaiodimou; Ioanna Tsantzali; Eleni Sideri; Anastasios Bonakis; Sotirios Giannopoulos; Konstantinos I. Voumvourakis; Georgios Tsivgoulis; Socrates J. Tzartos; Elisabeth Kapaki; George P. Paraskevas

doi:https://doi.org/10.3390/biom12081099

Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders

John S. Tzartos, Fotini Boufidou, Christos Stergiou, Jens Kuhle, Eline Willemse, Lina Palaiodimou, Ioanna Tsantzali, Eleni Sideri, Anastasios Bonakis, Sotirios Giannopoulos, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, Socrates J. Tzartos, Elisabeth Kapaki, George P. Paraskevas

Laboratory Medicine (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Blood phospho-tau181 may offer a useful biomarker for Alzheimer's disease. However, the use of either serum or plasma phospho-tau181 and their diagnostic value are currently under intense investigation. In a pilot study, we measured both serum and plasma phospho-tau181 (pT181-Tau) by single molecule array (Simoa) in a group of patients with Alzheimer's disease and a mixed group of patients with other primary dementing and/or movement disorders. Classical cerebrospinal fluid biomarkers were also measured. Plasma (but not serum) pT181-Tau showed a significant increase in Alzheimer's disease and correlated significantly with cerebrospinal fluid amyloid and pT181-Tau. Receiver operating curve analysis revealed a significant discrimination of Alzheimer's from non-Alzheimer's disease patients, with an area under the curve of 0.83 and an excellent sensitivity but a moderate specificity. Plasma pT181-Tau is not an established diagnostic biomarker for Alzheimer's disease, but it could become one in the future, or it may serve as a screening tool for specific cases of patients or presymptomatic subjects.

Original language	English
Article number	1099
Journal	BIOMOLECULES
Volume	12
Issue number	8
DOIs	https://doi.org/10.3390/biom12081099
Publication status	Published - 10 Aug 2022

Keywords

Alzheimer’s disease
biomarkers
dementia
phospho-tau
plasma

Access to Document

https://doi.org/10.3390/biom12081099

Cite this

Tzartos, J. S., Boufidou, F., Stergiou, C., Kuhle, J., Willemse, E., Palaiodimou, L., Tsantzali, I., Sideri, E., Bonakis, A., Giannopoulos, S., Voumvourakis, K. I., Tsivgoulis, G., Tzartos, S. J., Kapaki, E., & Paraskevas, G. P. (2022). Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders. BIOMOLECULES, 12(8), [1099]. https://doi.org/10.3390/biom12081099

@article{afe7054ffb224277a588a0d4e4ee5a22,

title = "Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders",

abstract = "Blood phospho-tau181 may offer a useful biomarker for Alzheimer's disease. However, the use of either serum or plasma phospho-tau181 and their diagnostic value are currently under intense investigation. In a pilot study, we measured both serum and plasma phospho-tau181 (pT181-Tau) by single molecule array (Simoa) in a group of patients with Alzheimer's disease and a mixed group of patients with other primary dementing and/or movement disorders. Classical cerebrospinal fluid biomarkers were also measured. Plasma (but not serum) pT181-Tau showed a significant increase in Alzheimer's disease and correlated significantly with cerebrospinal fluid amyloid and pT181-Tau. Receiver operating curve analysis revealed a significant discrimination of Alzheimer's from non-Alzheimer's disease patients, with an area under the curve of 0.83 and an excellent sensitivity but a moderate specificity. Plasma pT181-Tau is not an established diagnostic biomarker for Alzheimer's disease, but it could become one in the future, or it may serve as a screening tool for specific cases of patients or presymptomatic subjects.",

keywords = "Alzheimer{\textquoteright}s disease, biomarkers, dementia, phospho-tau, plasma",

author = "Tzartos, {John S.} and Fotini Boufidou and Christos Stergiou and Jens Kuhle and Eline Willemse and Lina Palaiodimou and Ioanna Tsantzali and Eleni Sideri and Anastasios Bonakis and Sotirios Giannopoulos and Voumvourakis, {Konstantinos I.} and Georgios Tsivgoulis and Tzartos, {Socrates J.} and Elisabeth Kapaki and Paraskevas, {George P.}",

note = "Funding Information: S.J.T. has received research funding by a grant from the Network of European Funding for Neuroscience Research ERA-NET NEURON JTC 2019 and Greek national funds through the EPANEK, under the priority axis: Enhancing entrepreneurship with sectoral priorities (project number: MIS 5075033). E.K. has received research funding from ELPEN Pharmaceutical Co. Inc. and NUTRICIA (funding numbers: 33/22-10-20 and 726/20-11-20, respectively). Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = aug,

day = "10",

doi = "https://doi.org/10.3390/biom12081099",

language = "English",

volume = "12",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "8",

}

Tzartos, JS, Boufidou, F, Stergiou, C, Kuhle, J, Willemse, E, Palaiodimou, L, Tsantzali, I, Sideri, E, Bonakis, A, Giannopoulos, S, Voumvourakis, KI, Tsivgoulis, G, Tzartos, SJ, Kapaki, E & Paraskevas, GP 2022, 'Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders', BIOMOLECULES, vol. 12, no. 8, 1099. https://doi.org/10.3390/biom12081099

TY - JOUR

T1 - Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders

AU - Tzartos, John S.

AU - Boufidou, Fotini

AU - Stergiou, Christos

AU - Kuhle, Jens

AU - Willemse, Eline

AU - Palaiodimou, Lina

AU - Tsantzali, Ioanna

AU - Sideri, Eleni

AU - Bonakis, Anastasios

AU - Giannopoulos, Sotirios

AU - Voumvourakis, Konstantinos I.

AU - Tsivgoulis, Georgios

AU - Tzartos, Socrates J.

AU - Kapaki, Elisabeth

AU - Paraskevas, George P.

N1 - Funding Information: S.J.T. has received research funding by a grant from the Network of European Funding for Neuroscience Research ERA-NET NEURON JTC 2019 and Greek national funds through the EPANEK, under the priority axis: Enhancing entrepreneurship with sectoral priorities (project number: MIS 5075033). E.K. has received research funding from ELPEN Pharmaceutical Co. Inc. and NUTRICIA (funding numbers: 33/22-10-20 and 726/20-11-20, respectively). Publisher Copyright: © 2022 by the authors.

PY - 2022/8/10

Y1 - 2022/8/10

N2 - Blood phospho-tau181 may offer a useful biomarker for Alzheimer's disease. However, the use of either serum or plasma phospho-tau181 and their diagnostic value are currently under intense investigation. In a pilot study, we measured both serum and plasma phospho-tau181 (pT181-Tau) by single molecule array (Simoa) in a group of patients with Alzheimer's disease and a mixed group of patients with other primary dementing and/or movement disorders. Classical cerebrospinal fluid biomarkers were also measured. Plasma (but not serum) pT181-Tau showed a significant increase in Alzheimer's disease and correlated significantly with cerebrospinal fluid amyloid and pT181-Tau. Receiver operating curve analysis revealed a significant discrimination of Alzheimer's from non-Alzheimer's disease patients, with an area under the curve of 0.83 and an excellent sensitivity but a moderate specificity. Plasma pT181-Tau is not an established diagnostic biomarker for Alzheimer's disease, but it could become one in the future, or it may serve as a screening tool for specific cases of patients or presymptomatic subjects.

AB - Blood phospho-tau181 may offer a useful biomarker for Alzheimer's disease. However, the use of either serum or plasma phospho-tau181 and their diagnostic value are currently under intense investigation. In a pilot study, we measured both serum and plasma phospho-tau181 (pT181-Tau) by single molecule array (Simoa) in a group of patients with Alzheimer's disease and a mixed group of patients with other primary dementing and/or movement disorders. Classical cerebrospinal fluid biomarkers were also measured. Plasma (but not serum) pT181-Tau showed a significant increase in Alzheimer's disease and correlated significantly with cerebrospinal fluid amyloid and pT181-Tau. Receiver operating curve analysis revealed a significant discrimination of Alzheimer's from non-Alzheimer's disease patients, with an area under the curve of 0.83 and an excellent sensitivity but a moderate specificity. Plasma pT181-Tau is not an established diagnostic biomarker for Alzheimer's disease, but it could become one in the future, or it may serve as a screening tool for specific cases of patients or presymptomatic subjects.

KW - Alzheimer’s disease

KW - biomarkers

KW - dementia

KW - phospho-tau

KW - plasma

UR - http://www.scopus.com/inward/record.url?scp=85137124821&partnerID=8YFLogxK

U2 - https://doi.org/10.3390/biom12081099

DO - https://doi.org/10.3390/biom12081099

M3 - Article

C2 - 36008993

SN - 2218-273X

VL - 12

JO - Biomolecules

JF - Biomolecules

IS - 8

M1 - 1099

ER -

Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders

Abstract

Keywords

Access to Document

Other files and links

Cite this